TABLE 4.
Six‐month outcomes
|
Enoxaparin n = 3526 |
Dalteparin or tinzaparin n = 925 |
|
|---|---|---|
| Main outcome, n (%) | ||
| Recurrent VTE a | 70 (2.0) | 23 (2.5) |
| Secondary outcomes | ||
| Recurrent DVT b | 36 (1.0) | 11 (1.2) |
| Recurrent PE c | 35 (0.99) | 12 (1.3) |
| Safety outcomes | ||
| Major bleeding c | 111 (3.1) | 18 (1.9) |
| Recurrent VTE or major bleeding | 181 (5.1) | 41 (4.4) |
| Nonmajor bleeding | 87 (2.5) | 24 (2.6) |
| All‐cause death | 666 (19) | 157 (17) |
| Cause of death | ||
| Pulmonary embolism | 33 (0.94) | 6 (0.65) |
| Bleeding | 15 (0.43) | 5 (0.54) |
| Fatal PE or fatal bleeding | 48 (1.4) | 11 (1.2) |
| Sudden, unexpected death | 3 (0.09) | 3 (0.32) |
Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism.
a
Composite effectiveness outcome = symptomatic DVT and fatal or nonfatal PE.
b
Symptomatic.
c
Fatal and nonfatal.